newsfilter
← Latest News
Business Wire·

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Xencor, Inc. ("Xencor") (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously